Pelthos Therapeutics Inc. (PTHS)
PTHS trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$20.29
+3.94% on the day
Market cap
$77.7M
Micro cap
Revenue · 2025
$16.8M
Prior year not contiguous
Net income · 2025
-$43.3M
-257.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | PTHS on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Not reported by the screener |
| IPO year | 2024 |
| SEC CIK | 0001919246 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $16.8M |
| Net income | -$43.3M |
| Operating income | -$32.4M |
| Net margin | -257.9% |
| Operating margin | -193.1% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $18.0M |
| Total assets | $130.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-02-13 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-10-01 |
| Latest proxy | DEFA14A | 2026-08-18 |
Source: SEC EDGAR submissions feed, 249 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRDF | Cardiff Oncology Inc. | $1.01 | -2.88% | $78.6M |
| CGTX | Cognition Therapeutics Inc. | $0.8017 | -6.44% | $76.2M |
| OKYO | OKYO Pharma Limited | $1.44 | -0.17% | $75.4M |
| GRML | Greenland Mines Ltd. | $5.54 | -7.97% | $73.9M |
| NMRA | Neumora Therapeutics Inc. | $0.3702 | -15.34% | $69.6M |
| CSBR | Champions Oncology Inc. | $4.90 | -1.08% | $68.2M |
| ATRA | Atara Biotherapeutics Inc. | $9.30 | -0.80% | $93.4M |
| BDTX | Black Diamond Therapeutics Inc. | $1.68 | -5.08% | $96.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier